{"schema_version":"secwatch.filing_event.v1","accession":"0000950142-22-000983","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2022-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.931418+00:00","generated_at":"2026-06-27T00:27:42.463250+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NRx CEO Javitt retires; Robert Besthof named interim CEO; narrows focus to US","bullets":["Dr. Jonathan Javitt retired as CEO effective March 8, 2022; becomes Chief Scientist and remains on Board.","Robert Besthof, Head of Operations, appointed Interim CEO; received 100,000 stock options at $2.61/share.","Javitt consulting agreement: $250,000 upfront plus $75,000/month for one year.","Company narrows geographic focus to US; ceasing efforts in Georgia and Caucasus due to geopolitical environment.","Continues development of ZYESAMI for Critical COVID-19 and psychiatric pipeline including NRX-101."],"urls":{"canonical":"https://secwatch.observer/filing/0000950142-22-000983","json":"https://secwatch.observer/filing/0000950142-22-000983.json","markdown":"https://secwatch.observer/filing/0000950142-22-000983.md","text":"https://secwatch.observer/filing/0000950142-22-000983.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000095014222000983/0000950142-22-000983-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000095014222000983/eh220233089_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T00:27:42.463250+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7a4df64c38","claim":"Jonathan Javitt retired as Chief Scientist at NRX Pharmaceuticals, Inc..","evidence_excerpt":"On March 8, 2022, Dr. Jonathan Javitt, MD, MPH, announced his retirement from his position as Chief Executive Officer of NRx Pharmaceuticals, Inc. (the “ Company ”), effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000095014222000983/0000950142-22-000983-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Chief Scientist"}],"fact_type":"executive_change"},{"claim_id":"e5af038bfc","claim":"Robert Besthof was appointed as Interim Chief Executive Officer at NRX Pharmaceuticals, Inc..","evidence_excerpt":"On March 8, 2022, the Board appointed Mr. Robert Besthof to serve as Interim Chief Executive Officer of the Company during the transition.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000095014222000983/0000950142-22-000983-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}